Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 4

DMP115 in Patients With an Ejection Fraction Between 25%-40% to Evaluate the Use of Contrast Echocardiography to Assess Heart Function

NCT00401687 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this clinical research study is to demonstrate the ability of Definity® enhanced versus unenhanced cardiac ultrasound to improve the accuracy and reproducibility of left ventricular ejection fraction (EF) when compared to magnetic resonance imaging (MRI).

Interventions

  • DRUG Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension

Study Locations (10)

Arizona

  • University of Arizona — Tucson

Illinois

  • University of Chicago Medical Center — Chicago

Maryland

  • Washington Hospital Center — Washington DC

Missouri

  • Saint Lukes Mid America Heart Institute — Kansas City

Nebraska

  • University of Nebraska Medical Center — Omaha

North Carolina

  • Duke University Medical Center — Durham

Ohio

  • Cleveland Clinic Foundation — Cleveland

Oregon

  • Oregon Health & Science University — Portland

Trial Details

FieldValue
Enrollment Target 131 participants
Start Date 2006-07
Est. Completion 2008-04
Phase Phase 4

Sponsor

Lantheus Medical Imaging

32 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00401687

The ClinicalTrials.gov registry entry for NCT00401687 describes a study currently listed as completed. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lantheus Medical Imaging, which has 32 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Ventricular Ejection Fraction appearing as the primary indexed condition, and to 1 intervention — of which Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00401687 reports 10 study locations spanning 10 distinct geographic areas — top geographies include Arizona, Illinois, Maryland. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00401687 about?

NCT00401687 is a clinical study titled "DMP115 in Patients With an Ejection Fraction Between 25%-40% to Evaluate the Use of Contrast Echocardiography to Assess Heart Function". The purpose of this clinical research study is to demonstrate the ability of Definity® enhanced versus unenhanced cardiac ultrasound to improve the accuracy and reproducibility of left ventricular ejection fraction (EF) when compared to magnetic resonance imaging (MRI).

What is the current status of trial NCT00401687?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 131 participants. The study started on 2006-07. Estimated completion is 2008-04.

What conditions does trial NCT00401687 study?

This clinical trial studies the following conditions: Ventricular Ejection Fraction. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00401687?

The interventions under investigation include: Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00401687?

This trial is sponsored by Lantheus Medical Imaging, which has 32 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00401687 being conducted?

This trial has 10 study locations across Arizona, Illinois, Maryland, Missouri, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial